1. MHC II−, but not MHC II+, hepatic Stellate cells contribute to liver fibrosis of mice in infection with Schistosoma japonicum.
- Author
-
Zhou, Chun-Lei, Kong, De-Long, Liu, Jin-Feng, Lu, Zhong-Kui, Guo, Hong-Fei, Wang, Wei, Qiu, Jing-Fan, Liu, Xin-Jian, and Wang, Yong
- Subjects
- *
KUPFFER cells , *SCHISTOSOMA japonicum , *MAJOR histocompatibility complex , *MYOFIBROBLASTS , *LABORATORY mice - Abstract
Hepatic stellate cells (HSCs) are considered as the main effector cells in vitamin A metabolism and liver fibrosis, as well as in hepatic immune regulation. Recently, researches have revealed that HSCs have plasticity and heterogeneity, which depend on their lobular location and whether liver is normal or injured. This research aimed to explore the biological characteristics and heterogeneity of HSCs in mice with Schistosoma japonicum ( S. japonicum ) infection, and determine the subpopulation of HSCs in pathogenesis of hepatic fibrosis caused by S. japonicum infection. Results revealed that HSCs significantly increased the expressions of MHC II and fibrogenic genes after S. japonicum infection, and could be classified into MHC II + HSCs and MHC II − HSCs subsets. Both two HSCs populations suppressed the proliferation of activated CD4 + T cells, whereas only MHC II − HSCs displayed a myofibroblast-like phenotype. In response to IFN-γ, HSCs up-regulated the expressions of MHC II and CIITA , while down-regulated the expression of fibrogenic gene Col1 . In addition, praziquantel treatment decreased the expressions of fibrogenic genes in MHC II − HSCs. These results confirmed that HSCs from S. japonicum -infected mice have heterogeneity. The MHC II − α-SMA + HSCs were major subsets of HSCs contributing to liver fibrosis and could be considered as a potential target of praziquantel anti-fibrosis treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF